Innovative Bioprinting Prellis Biologics leverages proprietary high-resolution 3D bioprinting technology to recreate and engineer human tissues, presenting a unique platform for customized tissue models and regenerative medicine solutions that could be valuable for partners in cell therapy and organ engineering.

Strong Funding and Backing With a recent $35 million Series C funding round led by prominent venture capital firms like Khosla Ventures and True Ventures, the company demonstrates solid financial backing, indicating potential for scaled collaborations and joint development projects with biotech enterprises seeking innovative R&D tools.

Collaboration with Biotech Giants Prellis has established strategic partnerships with major players such as Sanofi and Bristol-Myers Squibb for drug discovery and immune system research, offering sales opportunities in licensing, joint research, and platform integration for pharmaceutical companies focused on immuno-oncology and biologics.

Expanding Platform Capabilities The company is actively expanding its EXIS platform to encompass applications in antibody discovery, immunogenicity testing, and vaccine screening, creating multiple entry points for sales of bioprocessing, assay development, and immunology-focused services to biotech firms and research institutions.

Sector Focus and Market Potential Targeting the biotech and pharmaceutical industry with a focus on immune system modeling and tissue engineering, Prellis offers opportunities for vendors of lab equipment, software solutions, and biomanufacturing tools to tap into a rapidly growing market driven by advances in personalized medicine and regenerative therapies.